Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis.
TLDR
In this article, the authors discussed the current trend of therapeutic development for psoriasis based on the recent discoveries in the immune modulation of the inflammatory response in psoriatic skin disorders.Abstract:
Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2-3% of the global population, is thought to be genetically predetermined and induced by environmental and immunological factors. In the past decades, basic and clinical studies have significantly expanded knowledge on the molecular, cellular, and immunological mechanisms underlying the pathogenesis of psoriasis. Based on these pathogenic mechanisms, the current disease model emphasizes the role of aberrant Th1 and Th17 responses. Th1 and Th17 immune responses are regulated by a complex network of different cytokines, including TNF-α, IL-17, and IL-23; signal transduction pathways downstream to the cytokine receptors; and various activated transcription factors, including NF-κB, interferon regulatory factors (IRFs), and signal transducer and activator of transcriptions (STATs). The biologics developed to specifically target the cytokines have achieved a better efficacy and safety for the systemic management of psoriasis compared with traditional treatments. Nevertheless, the current therapeutics can only alleviate the symptoms; there is still no cure for psoriasis. Therefore, the development of more effective, safe, and affordable therapeutics for psoriasis is important. In this review, we discussed the current trend of therapeutic development for psoriasis based on the recent discoveries in the immune modulation of the inflammatory response in psoriasis.read more
Citations
More filters
Journal ArticleDOI
Skin Barrier Dysregulation in Psoriasis
TL;DR: In this article, the authors summarize recent discoveries in disease pathogenesis, including the contribution of keratinocytes, immune cells, genetic and environmental factors, and how they advance current and future treatments.
Journal ArticleDOI
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Hideyuki Ujiie,David H. Rosmarin,Michael P. Schön,Sonja Ständer,Katharina Boch,Martin Metz,Marcus Maurer,Diamant Thaçi,R. Schmidt,C. Cole,Kyle T. Amber,Dario Didona,Michael Hertl,Andreas Recke,Hanna Grasshoff,Alexander Hackel,Anja Schumann,Gabriela Riemekasten,Katja Bieber,Gant Sprow,Joshua Dan,Detlef Zillikens,Tanya Sezin,Angela M. Christiano,Kerstin Wolk,Robert Sabat,Khalaf Kridin,Victoria P. Werth,Ralf Ludwig +28 more
TL;DR: A significant improvement in diagnosis and treatment of chronic inflammatory skin diseases is seen, but several challenges remain, including insufficient therapeutic responses and relapses.
Journal ArticleDOI
Current developments and perspectives in psoriasis
TL;DR: In this article , the authors summarized the main features of current psoriasis research with emphasis on pathophysiological processes and the milestones in the approval of various biologics and small molecule drugs.
Journal ArticleDOI
Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper
Jensen Yeung,Marc Bourcier,Melinda Gooderham,Parbeer Grewal,Chih-Ho Hong,Perla Lansang,Charles Lynde,Catherine Maari,Vimal H. Prajapati,Irina Turchin,Ronald Vender +10 more
TL;DR: In this article , the authors developed consensus recommendations for implementing T2T strategies for the management of moderate-to-severe plaque psoriasis using biologics, and proposed a criterion-based system for determining the achievement of treatment target.
Journal ArticleDOI
Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study.
Takemichi Fukasawa,Satoshi Toyama,Atsushi Enomoto,Asako Yoshizaki-Ogawa,Yuta Norimatsu,Shoko Tateishi,Hiroko Kanda,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki +9 more
TL;DR: In this paper , a prospective cohort study was conducted to evaluate the clinical significance of nailfold capillary (NFC) changes in patients with psoriasis, and the correlation of NFC abnormalities, including nailfold bleeding (NFB) and enlarged capillaries, with the prevalence of psoriatic arthritis, incidence of new PsA and serum levels of TNF-a, IL-17A, and IL-23 were analyzed.
References
More filters
Journal ArticleDOI
Mechanisms of type-I- and type-II-interferon-mediated signalling.
TL;DR: It is anticipated that an increased understanding of the contributions of these recently identified pathways will advance current thinking about how interferons work.
Journal ArticleDOI
Mechanisms of Disease: Psoriasis.
TL;DR: Anti-TNF strategies have three variants: a humanized chimeric anti–TNF- α monoclonal antibody, a fully human monocolonal anti-T NF- α antibody, and a human p75 TNF-receptor Fc fusion protein.
Journal ArticleDOI
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.
Norimitsu Kadowaki,Stephen Ho,Svetlana Antonenko,Rene de Waal Malefyt,Robert A. Kastelein,J. Fernando Bazan,Yong-Jun Liu +6 more
TL;DR: The expression of distinct sets of TLRs and the corresponding difference in reactivity to microbial molecules among subsets of pre-DCs and imDCs support the concept that they have developed through distinct evolutionary pathways to recognize different microbial antigens.
Journal ArticleDOI
The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation
TL;DR: The discovery of a novel 34 kDa protein, designated TRADD, that specifically interacts with an intracellular domain of TNFR1 known to be essential for mediating programmed cell death shows that the signaling pathways for TNF-induced cell death and NF-κB activation are distinct.
Journal ArticleDOI
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
TL;DR: The data indicated that the occurrence of psoriasis varied according to age and geographic region, being more frequent in countries more distant from the equator and trends in incidence over time.